Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.860
-0.120 (-6.06%)
At close: Dec 5, 2025, 4:00 PM EST
1.920
+0.060 (3.23%)
After-hours: Dec 5, 2025, 7:31 PM EST
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of 7.67, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 312.37% from the current stock price of 1.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +330.11% | Nov 18, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +383.87% | Aug 25, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +115.05% | Jun 17, 2025 |
| UBS | UBS | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +115.05% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $11 | Strong Buy | Maintains | $15 → $11 | +491.40% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.09
from -1.71
EPS Next Year
-1.54
from -2.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.95 | -0.90 | |
| Avg | -2.09 | -1.54 | |
| Low | -2.13 | -1.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.